X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DIVIS LABORATORIES - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DIVIS LABORATORIES CIPLA/
DIVIS LABORATORIES
 
P/E (TTM) x 44.8 18.6 241.4% View Chart
P/BV x 3.7 4.0 92.0% View Chart
Dividend Yield % 0.3 1.5 22.6%  

Financials

 CIPLA   DIVIS LABORATORIES
EQUITY SHARE DATA
    CIPLA
Mar-17
DIVIS LABORATORIES
Mar-16
CIPLA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6222,484 25.0%   
Low Rs458918 49.9%   
Sales per share (Unadj.) Rs181.9142.3 127.8%  
Earnings per share (Unadj.) Rs12.941.9 30.7%  
Cash flow per share (Unadj.) Rs29.346.3 63.3%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.40.6 63.0%  
Book value per share (Unadj.) Rs155.7161.5 96.4%  
Shares outstanding (eoy) m804.51265.47 303.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.012.0 24.8%   
Avg P/E ratio x42.040.6 103.3%  
P/CF ratio (eoy) x18.436.7 50.2%  
Price / Book Value ratio x3.510.5 32.9%  
Dividend payout %15.523.9 65.1%   
Avg Mkt Cap Rs m434,516451,525 96.2%   
No. of employees `00023.03.7 621.4%   
Total wages/salary Rs m26,3383,649 721.8%   
Avg. sales/employee Rs Th6,349.110,184.4 62.3%   
Avg. wages/employee Rs Th1,143.0984.1 116.1%   
Avg. net profit/employee Rs Th449.32,998.5 15.0%   
INCOME DATA
Net Sales Rs m146,30237,764 387.4%  
Other income Rs m2,287848 269.6%   
Total revenues Rs m148,58938,612 384.8%   
Gross profit Rs m24,75814,138 175.1%  
Depreciation Rs m13,2291,182 1,119.4%   
Interest Rs m1,59423 6,869.8%   
Profit before tax Rs m12,22213,781 88.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7982,662 67.5%   
Profit after tax Rs m10,35411,119 93.1%  
Gross profit margin %16.937.4 45.2%  
Effective tax rate %14.719.3 76.1%   
Net profit margin %7.129.4 24.0%  
BALANCE SHEET DATA
Current assets Rs m87,37030,947 282.3%   
Current liabilities Rs m33,0815,195 636.8%   
Net working cap to sales %37.168.2 54.4%  
Current ratio x2.66.0 44.3%  
Inventory Days Days87117 74.5%  
Debtors Days Days6285 73.2%  
Net fixed assets Rs m111,56717,027 655.2%   
Share capital Rs m1,609531 303.1%   
"Free" reserves Rs m123,64542,341 292.0%   
Net worth Rs m125,25442,877 292.1%   
Long term debt Rs m36,4545 775,608.5%   
Total assets Rs m209,53249,684 421.7%  
Interest coverage x8.7595.0 1.5%   
Debt to equity ratio x0.30 265,506.2%  
Sales to assets ratio x0.70.8 91.9%   
Return on assets %5.722.4 25.4%  
Return on equity %8.325.9 31.9%  
Return on capital %8.532.2 26.4%  
Exports to sales %34.285.3 40.1%   
Imports to sales %8.322.9 36.4%   
Exports (fob) Rs m50,05032,198 155.4%   
Imports (cif) Rs m12,2038,654 141.0%   
Fx inflow Rs m51,06632,270 158.2%   
Fx outflow Rs m17,6788,775 201.5%   
Net fx Rs m33,38823,496 142.1%   
CASH FLOW
From Operations Rs m23,82410,379 229.5%  
From Investments Rs m-13,127-4,135 317.5%  
From Financial Activity Rs m-13,239-6,241 212.1%  
Net Cashflow Rs m-2,4783 -75,090.9%  

Share Holding

Indian Promoters % 16.0 52.0 30.8%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 11.8 103.4%  
FIIs % 23.7 19.0 124.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.2 152.3%  
Shareholders   161,166 31,796 506.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  UNICHEM LAB  MERCK LTD  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bank Stocks Witness Selling(01:30 pm)

After opening the day on a flat note, the Indian share markets have reversed the trend and are currently trading above the dotted line.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 17, 2017 03:07 PM

TRACK CIPLA

CIPLA - ABBOTT INDIA COMPARISON

COMPARE CIPLA WITH

MARKET STATS